HistoSonics just cleared a major Asia hurdle. Could histotripsy move beyond liver tumors next?
HistoSonics cleared Taiwan, but the bigger test is whether histotripsy can scale from liver tumors into broader oncology use.
HistoSonics is taking histotripsy beyond liver tumors. Kidney cancer care may be the next credibility test.
HistoSonics has liver clearance. Kidney tumors are the harder test, where non-invasive ambition must meet regulatory and clinical proof.